190 related articles for article (PubMed ID: 24029871)
1. Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients.
Kwakernaak AJ; Waanders F; Slagman MC; Dokter MM; Laverman GD; de Boer RA; Navis G
J Hypertens; 2013 Dec; 31(12):2425-32. PubMed ID: 24029871
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
[TBL] [Abstract][Full Text] [Related]
3. Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients.
Slagman MC; Waanders F; Vogt L; Damman K; Hemmelder M; Navis G; Laverman GD
Nephrol Dial Transplant; 2012 Mar; 27(3):983-90. PubMed ID: 21862455
[TBL] [Abstract][Full Text] [Related]
4. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
5. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels.
Gant CM; Laverman GD; Vogt L; Slagman MCJ; Heerspink HJL; Waanders F; Hemmelder MH; Navis G;
BMC Nephrol; 2017 Dec; 18(1):370. PubMed ID: 29262813
[TBL] [Abstract][Full Text] [Related]
6. Effects of Dietary Sodium Restriction in Kidney Transplant Recipients Treated With Renin-Angiotensin-Aldosterone System Blockade: A Randomized Clinical Trial.
de Vries LV; Dobrowolski LC; van den Bosch JJ; Riphagen IJ; Krediet CT; Bemelman FJ; Bakker SJ; Navis G
Am J Kidney Dis; 2016 Jun; 67(6):936-44. PubMed ID: 26803690
[TBL] [Abstract][Full Text] [Related]
7. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial.
Kwakernaak AJ; Krikken JA; Binnenmars SH; Visser FW; Hemmelder MH; Woittiez AJ; Groen H; Laverman GD; Navis G;
Lancet Diabetes Endocrinol; 2014 May; 2(5):385-95. PubMed ID: 24795252
[TBL] [Abstract][Full Text] [Related]
8. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
Onuigbo MA; Onuigbo NT
QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
[TBL] [Abstract][Full Text] [Related]
9. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.
Slagman MC; Waanders F; Hemmelder MH; Woittiez AJ; Janssen WM; Lambers Heerspink HJ; Navis G; Laverman GD;
BMJ; 2011 Jul; 343():d4366. PubMed ID: 21791491
[TBL] [Abstract][Full Text] [Related]
10. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Junot C; Ezan E; Ménard J
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
[TBL] [Abstract][Full Text] [Related]
12. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.
Azizi M; Ezan E; Reny JL; Wdzieczak-Bakala J; Gerineau V; Ménard J
Hypertension; 1999 Mar; 33(3):879-86. PubMed ID: 10082503
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol.
Keyzer CA; de Jong MA; Fenna van Breda G; Vervloet MG; Laverman GD; Hemmelder M; Janssen WM; Lambers Heerspink HJ; Navis G; de Borst MH;
Nephrol Dial Transplant; 2016 Jul; 31(7):1081-7. PubMed ID: 25744274
[TBL] [Abstract][Full Text] [Related]
14. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial.
Waanders F; Vaidya VS; van Goor H; Leuvenink H; Damman K; Hamming I; Bonventre JV; Vogt L; Navis G
Am J Kidney Dis; 2009 Jan; 53(1):16-25. PubMed ID: 18823687
[TBL] [Abstract][Full Text] [Related]
15. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
Slagman MC; Navis G; Laverman GD
Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
[TBL] [Abstract][Full Text] [Related]
16. Benefits of dietary sodium restriction in the management of chronic kidney disease.
Krikken JA; Laverman GD; Navis G
Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):531-8. PubMed ID: 19713840
[TBL] [Abstract][Full Text] [Related]
17. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice.
Onuigbo MA
Hemodial Int; 2009 Oct; 13 Suppl 1():S24-9. PubMed ID: 19775421
[TBL] [Abstract][Full Text] [Related]
18. Sodium restriction potentiates the renoprotective effects of combined vitamin D receptor activation and angiotensin-converting enzyme inhibition in established proteinuric nephropathy.
Mirkovic K; Frenay AS; van den Born J; van Goor H; Navis G; de Borst MH;
Nephrol Dial Transplant; 2017 Aug; 32(8):1293-1301. PubMed ID: 26311058
[TBL] [Abstract][Full Text] [Related]
19. Sodium intake, RAAS-blockade and progressive renal disease.
de Borst MH; Navis G
Pharmacol Res; 2016 May; 107():344-351. PubMed ID: 27041482
[TBL] [Abstract][Full Text] [Related]
20. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.
van den Heuvel M; Batenburg WW; Jainandunsing S; Garrelds IM; van Gool JM; Feelders RA; van den Meiracker AH; Danser AH
J Hypertens; 2011 Nov; 29(11):2147-55. PubMed ID: 21941204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
